ZL 2302

Drug Profile

ZL 2302

Alternative Names: ZL2302

Latest Information Update: 11 Dec 2015

Price : $50

At a glance

  • Originator Sanofi
  • Developer ZAI Lab
  • Class Antineoplastics
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 11 Dec 2015 Preclinical trials in Non-small cell lung cancer in China (unspecified route) (ZAI Lab pipeline, December 2015)
  • 31 Jul 2015 ZL-2302 licensed to ZAI Lab
  • 31 Jul 2015 Early research in Non-small cell lung cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top